BIO-PATH HOLDINGS, INC.
BPTHNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for BPTH. That does not mean none is planned.
Get an email about BPTH's next catalysts
Track BIO-PATH HOLDINGS (BPTH) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
BP1001 in combination with Ventoclax plus decitabine
Acute Myeloid Leukemia (AML)
BP1001 plus decitabine
Acute Myeloid Leukemia (AML)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BP1001 in combination with Ventoclax plus decitabine | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
BP1001 plus decitabine | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
Frequently asked questions
What is in BIO-PATH HOLDINGS, INC.'s drug pipeline?β
CatalystAlert tracks 2 drug candidates in BIO-PATH HOLDINGS, INC.'s (BPTH) pipeline across Phase 2. Its lead program is BP1001 in combination with Ventoclax plus decitabine (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BIO-PATH HOLDINGS, INC.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for BIO-PATH HOLDINGS, INC. (BPTH) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track BPTH biotech catalysts?β
Add BPTH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BIO-PATH HOLDINGS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
